ZITUVIO Trademark

Trademark Overview

On Thursday, April 28, 2022, a trademark application was filed for ZITUVIO with the United States Patent and Trademark Office. The USPTO has given the ZITUVIO trademark a serial number of 97386962. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Friday, March 29, 2024. This trademark is owned by Zydus Pharmaceuticals (USA) Inc.. The ZITUVIO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of diabetes only, not for intravenous administration or administration by infusion; none of the foregoing for treatment, or any associated treatment, of blood disorders or immunological diseases
zituvio

General Information

Serial Number97386962
Word MarkZITUVIO
Filing DateThursday, April 28, 2022
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateFriday, March 29, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 21, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of diabetes only, not for intravenous administration or administration by infusion; none of the foregoing for treatment, or any associated treatment, of blood disorders or immunological diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 3, 2022
Primary Code005
First Use Anywhere DateThursday, December 21, 2023
First Use In Commerce DateThursday, December 21, 2023

Trademark Owner History

Party NameZydus Pharmaceuticals (USA) Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPennington, NJ 08534
Party NameZydus Pharmaceuticals (USA) Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPennington, NJ 08534

Trademark Events

Event DateEvent Description
Saturday, March 30, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Friday, March 29, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, February 29, 2024STATEMENT OF USE PROCESSING COMPLETE
Monday, February 5, 2024USE AMENDMENT FILED
Saturday, February 24, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, February 5, 2024TEAS STATEMENT OF USE RECEIVED
Friday, January 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 3, 2024SOU EXTENSION 1 GRANTED
Wednesday, January 3, 2024SOU EXTENSION 1 FILED
Wednesday, January 3, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 3, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, January 3, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 3, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, January 3, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, August 1, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, June 22, 2023EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, June 13, 2023CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Monday, June 12, 2023ASSIGNED TO PETITION STAFF
Thursday, May 25, 2023TEAS POST PUBLICATION AMENDMENT RECEIVED
Wednesday, April 19, 2023EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, March 21, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 21, 2023PUBLISHED FOR OPPOSITION
Wednesday, March 1, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, February 16, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 15, 2023ASSIGNED TO EXAMINER
Tuesday, May 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, May 2, 2022NEW APPLICATION ENTERED

Related Keywords

zituvio treatment administration associated blood immunological diseases foregoing disorders infusion diabetes